Expand LEXX Menu
LEXX MENU

LEXX Latest Press Releases

-- December 9, 2024 --

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 ACCESSWIRE 9:12 AM

-- November 26, 2024 --

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs ACCESSWIRE 9:20 AM

-- November 25, 2024 --

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled ACCESSWIRE 9:01 AM

-- November 20, 2024 --

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study ACCESSWIRE 9:05 AM

-- November 14, 2024 --

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study ACCESSWIRE 9:11 AM

-- November 13, 2024 --

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss ACCESSWIRE 9:21 AM

-- November 7, 2024 --

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments ACCESSWIRE 9:19 AM

-- October 24, 2024 --

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study ACCESSWIRE 9:20 AM

-- October 22, 2024 --

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study ACCESSWIRE 9:21 AM

-- October 16, 2024 --

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules ACCESSWIRE 4:00 PM

-- October 15, 2024 --

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules ACCESSWIRE 8:26 AM

-- October 9, 2024 --

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing ACCESSWIRE 9:06 AM

-- October 8, 2024 --

Lexaria Updates Current GLP-1 Market ACCESSWIRE 9:21 AM

-- October 1, 2024 --

Lexaria Appoints Michael Shankman as Chief Financial Officer ACCESSWIRE 9:26 AM

-- September 27, 2024 --

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 ACCESSWIRE 9:22 AM

-- September 5, 2024 --

Lexaria Releases Strategic Letter from the Outgoing CEO ACCESSWIRE 10:02 AM

-- September 3, 2024 --

Lexaria Enters a Material Transfer Agreement for DehydraTECH Research ACCESSWIRE 8:48 AM

-- August 30, 2024 --

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules ACCESSWIRE 8:30 AM

-- August 29, 2024 --

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules ACCESSWIRE 9:27 AM

-- August 27, 2024 --

First Results from Lexaria's Second GLP-1 Human Pilot Study ACCESSWIRE 9:21 AM

-- August 22, 2024 --

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study ACCESSWIRE 9:22 AM

-- August 19, 2024 --

Positive Results from Lexaria's Molecular Characterization Study ACCESSWIRE 9:06 AM

-- July 17, 2024 --

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study ACCESSWIRE 10:32 AM

-- July 16, 2024 --

Lexaria Preparing For Strategic Growth ACCESSWIRE 9:21 AM